鹿田：造血器腫瘍治療の変遷南予医誌 Vol.15 No. １ 2014－9－of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453-2463.20） Rummel MJ, Niederle N, Maschmey-er G, et al.: Bendamustine plus ritux-imab versus CHOP plus rituximab as rst-line treatment for patients with in-dolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.Progress in treatment for hematologic malig-nancies: Focusing on targeted therapies Hisaharu SHIKATA Department of Hematology Uwajima city hospital Goten-machi, Uwajima, Ehime 798-8510, JAPAN（Nan-yo Med J 2014; 15: 1-9.）
元のページ ../index.html#11